Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Preferred Stock Liabilities (2022)

Orchestra BioMed Holdings (OBIO) has disclosed Preferred Stock Liabilities for 1 consecutive years, with $67.7 million as the latest value for Q4 2022.

  • Quarterly Preferred Stock Liabilities changed N/A to $67.7 million in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $67.7 million through Dec 2022, changed N/A year-over-year, with the annual reading at $67.7 million for FY2022, N/A changed from the prior year.
  • Preferred Stock Liabilities for Q4 2022 was $67.7 million at Orchestra BioMed Holdings, roughly flat from $67.7 million in the prior quarter.
  • The five-year high for Preferred Stock Liabilities was $160.1 million in Q2 2022, with the low at $67.7 million in Q3 2022.